Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
View: Text | PDF
Research Article Pulmonology Vascular biology

Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes

  • Text
  • PDF
Abstract

Endothelial progenitor cells (EPCs) are critical for vascular regeneration after injury. However, their role in pulmonary fibrosis (PF) remains unclear. Here, we identified a previously unrecognized population of lung capillary EPCs coexpressing c-KIT and FOXF1 (capEPCs) in adult human and mouse lungs. capEPCs were significantly reduced in lungs from patients with PF and in bleomycin-injured mice, implicating loss of this regenerative endothelial population in disease pathogenesis. Transplantation of donor capEPCs attenuated experimental PF, improved survival, reduced collagen deposition, and restored lung function. Donor capEPCs engrafted into the lung microcirculation of bleomycin-injured mice. Single-cell RNA sequencing identified interferon-induced transmembrane protein 3 as a highly enriched transcript in capEPCs. Conditioned media from IFITM3-overexpressing EPCs or recombinant IFITM3 enhanced endothelial proliferation and angiogenesis while suppressing TGF-β1–induced fibroblast activation in vitro. IFITM3 was found in capEPC-derived exosomes. Treatment with IFITM3-containing exosomes recapitulated the therapeutic effects of capEPC transplantation by improving endothelial function, inhibiting fibroblast activation, increasing animal survival, reducing lung fibrosis, and restoring lung function. Together these findings identified capEPC deficiency as a feature of PF and demonstrated that IFITM3-containing exosomes promoted vascular repair. Restoration of capEPC regenerative function or delivery of IFITM3-enriched exosomes may represent a promising therapeutic strategy for human PF.

Authors

Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin

×

Figure 9

Treatment with IFITM3-containing exosomes decreases PF and improves survival in bleomycin-injured mice.

Options: View larger image (or click on image) Download as PowerPoint
Treatment with IFITM3-containing exosomes decreases PF and improves surv...
(A) Treatment with IFITM3-containing (IFITM3hi) exosomes attenuated body weight loss in mice after bleomycin (BLM) injury. Exosomes were delivered on days 8 and 11 after BLM treatment. (B) Survival was improved in mice treated with IFITM3hi exosomes compared with mice treated with IFITM3lo exosomes. Numbers in parentheses indicate surviving mice/total mice per group. (C) HiBiT luminescence in lung lysates on day 15 post-bleomycin confirmed presence of IFITM3-containing exosomes in lung tissue (IFITM3lo, n = 4; IFITM3hi, n = 5). (D) Oxygen saturation was increased in mice treated with IFITM3hi exosomes (IFITM3lo, n = 4; IFITM3hi, n = 6). (E–H) FlexiVent measurements on day 15 showed that IFITM3hi exosomes improved elastance (Ers) (E), resistance (Rrs) (F), static compliance (Cst) (G), and inspiratory capacity (IC) (H). Red and black dotted lines represent the average values of the bleomycin and wild-type (WT) groups, respectively. (I) Hydroxyproline assay revealed reduced collagen deposition in mice treated with IFITM3hi exosomes (IFITM3lo, n = 4; IFITM3hi, n = 5). (J) Representative H&E, Masson’s trichrome, and Sirius red/fast green staining of lungs collected on day 15. Scale bars: 100 μm. (K) Quantification of Ashcroft scores and trichrome and Sirius red areas from J. (L) qRT-PCR showed reduced Col1a1, Col3a1, Fn1, and Vim in the IFITM3hi exosome–treated mice. Expression was normalized to Actb. Data are presented as mean ± SD. IFITM3hi exosome–treated mice, n = 5; IFITM3lo exosome–treated mice, n = 4. For box-and-whisker plots in D, I, and K, boxes indicate the 25th to 75th percentiles, center lines indicate the medians, and whiskers indicate the minimum and maximum values. Unpaired 2-tailed t tests were used in C–I, K, and L. **P < 0.01, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts